-
1
-
-
30044449981
-
A multidimensional model for understanding cancer pain
-
Wool MS, Mor V. A multidimensional model for understanding cancer pain. Cancer Investigation. 2005; 23: 727-34
-
(2005)
Cancer Investigation
, vol.23
, pp. 727-734
-
-
Wool, M.S.1
Mor, V.2
-
2
-
-
0038615188
-
Pain, depression, and fatigue
-
NIH State-of-the-Science Statement on Symptom Management in Cancer. Pain, depression, and fatigue. NIH Consensus and State-of-the-Science Statements. 2002; 19: 1-29
-
(2002)
NIH Consensus and State-Of-The-Science Statements
, vol.19
, pp. 1-29
-
-
-
4
-
-
0003527864
-
-
2nd edn. Geneva: World Health Organization
-
World Health Organization. Cancer pain relief, 2nd edn. Geneva: World Health Organization, 1996
-
(1996)
Cancer Pain Relief
-
-
-
5
-
-
0035060745
-
Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness
-
Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness. Journal of Pain and Symptom Management. 2001; 21: 338-54
-
(2001)
Journal of Pain and Symptom Management
, vol.21
, pp. 338-354
-
-
Mercadante, S.1
Portenoy, R.K.2
-
6
-
-
0019439185
-
Unexpected complication of successful nerve block. Morphine induced respiratory depression precipitated by removal of severe pain
-
Hanks GW, Twycross RG, Lloyd JW. Unexpected complication of successful nerve block. Morphine induced respiratory depression precipitated by removal of severe pain. Anaesthesia. 1981; 36: 37-9
-
(1981)
Anaesthesia
, vol.36
, pp. 37-39
-
-
Hanks, G.W.1
Twycross, R.G.2
Lloyd, J.W.3
-
7
-
-
0034046878
-
Bedside perspectives on the use of opioids: Transferring results of clinical research into practice
-
Ravenscroft P, Schneider J. Bedside perspectives on the use of opioids: transferring results of clinical research into practice. Clinical and Experimental Pharmacology and Physiology. 2000; 27: 529-32
-
(2000)
Clinical and Experimental Pharmacology and Physiology
, vol.27
, pp. 529-532
-
-
Ravenscroft, P.1
Schneider, J.2
-
10
-
-
0028882923
-
The cloned mu, delta and kappa receptors and their endogenous ligands: Evidence for two opioid peptide recognition cores
-
Mansour A, Hoversten MT, Taylor LP et al. The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Research. 1995; 700: 89-98
-
(1995)
Brain Research
, vol.700
, pp. 89-98
-
-
Mansour, A.1
Hoversten, M.T.2
Taylor, L.P.3
-
11
-
-
0028971215
-
Orphanin FQ: A neuropeptide that activates an opioid-like G proteincoupled receptor
-
Reinscheid RK, Nothacker HP, Bourson A et al. Orphanin FQ: a neuropeptide that activates an opioid-like G proteincoupled receptor. Science. 1995; 270: 792-4
-
(1995)
Science
, vol.270
, pp. 792-794
-
-
Reinscheid, R.K.1
Nothacker, H.P.2
Bourson, A.3
-
12
-
-
0031553387
-
Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor
-
Meunier JC. Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. European Journal of Pharmacology. 1997; 340: 1-15
-
(1997)
European Journal of Pharmacology
, vol.340
, pp. 1-15
-
-
Meunier, J.C.1
-
13
-
-
0026550559
-
Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: Supraand sub-additivity
-
Horan P, Tallarida RJ, Haaseth RC et al. Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: supraand sub-additivity. Life Sciences. 1992; 50: 1535-41
-
(1992)
Life Sciences
, vol.50
, pp. 1535-1541
-
-
Horan, P.1
Tallarida, R.J.2
Haaseth, R.C.3
-
14
-
-
0031835859
-
Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord
-
He L, Lee NM. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord. Journal of Pharmacology and Experimental Therapeutics. 1998; 285: 1181-6
-
(1998)
Journal of Pharmacology and Experimental Therapeutics
, vol.285
, pp. 1181-1186
-
-
He, L.1
Lee, N.M.2
-
15
-
-
0030045115
-
An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice
-
Kest B, Lee CE, McLemore GL, Inturrisi CE. An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice. Brain Research Bulletin. 1996; 39: 185-8
-
(1996)
Brain Research Bulletin
, vol.39
, pp. 185-188
-
-
Kest, B.1
Lee, C.E.2
McLemore, G.L.3
Inturrisi, C.E.4
-
18
-
-
0033529255
-
The mu opiate receptor as a candidate gene for pain: Polymorphisms, variations in expression, nociception, and opiate responses
-
Uhl GR, Sora I, Wang Z. The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96: 7752-5
-
(1999)
Proceedings of the National Academy of Sciences of the United States of America
, vol.96
, pp. 7752-7755
-
-
Uhl, G.R.1
Sora, I.2
Wang, Z.3
-
19
-
-
33646833956
-
A highly selective kappaopioid receptor agonist with low addictive potential and dependence liability
-
Park HS, Lee HY, Kim YH et al. A highly selective kappaopioid receptor agonist with low addictive potential and dependence liability. Bioorganic and Medicinal Chemistry Letters. 2006; 16: 3609-13
-
(2006)
Bioorganic and Medicinal Chemistry Letters
, vol.16
, pp. 3609-3613
-
-
Park, H.S.1
Lee, H.Y.2
Kim, Y.H.3
-
20
-
-
33645070773
-
Opioid ligands with mixed mu/delta opioid receptor interactions: An emerging approach to novel analgesics
-
Ananthan S. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics. The AAPS Journal. 2006; 8: E118-25
-
(2006)
The AAPS Journal
, vol.8
, pp. E118-E125
-
-
Ananthan, S.1
-
21
-
-
0019845261
-
Both mu and delta opiate receptors exist on the same neuron
-
Egan TM, North RA. Both mu and delta opiate receptors exist on the same neuron. Science. 1981; 214: 923-4
-
(1981)
Science
, vol.214
, pp. 923-924
-
-
Egan, T.M.1
North, R.A.2
-
22
-
-
0034668742
-
Heterodimerization of mu and delta opioid receptors: A role in opiate synergy
-
Gomes I, Jordan BA, Gupta A et al. Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. Journal of Neuroscience. 2000; 20: RC110
-
(2000)
Journal of Neuroscience
, vol.20
-
-
Gomes, I.1
Jordan, B.A.2
Gupta, A.3
-
23
-
-
3042736193
-
Mu opiate receptor subtypes
-
Cadet P. Mu opiate receptor subtypes. Medical Science Monitor. 2004; 10: MS28-32
-
(2004)
Medical Science Monitor
, vol.10
, pp. MS28-MS32
-
-
Cadet, P.1
-
24
-
-
0035993849
-
Non-peptide opioid receptor ligands recent advances. Part I: Agonists
-
Kaczor A, Matosiuk D. Non-peptide opioid receptor ligands recent advances. Part I: agonists. Current Medicinal Chemistry. 2002; 9: 1567-89
-
(2002)
Current Medicinal Chemistry
, vol.9
, pp. 1567-1589
-
-
Kaczor, A.1
Matosiuk, D.2
-
25
-
-
0035252727
-
Incomplete cross tolerance and multiple mu opioid peptide receptors
-
Pasternak GW. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends in Pharmacological Sciences. 2001; 22: 67-70
-
(2001)
Trends in Pharmacological Sciences
, vol.22
, pp. 67-70
-
-
Pasternak, G.W.1
-
27
-
-
28444479463
-
Diversity and complexity of the mu opioid receptor gene: Alternative pre-mRNA splicing and promoters
-
Pan YX. Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters. DNA Cell Biology. 2005; 24: 736-50
-
(2005)
DNA Cell Biology
, vol.24
, pp. 736-750
-
-
Pan, Y.X.1
-
28
-
-
18844451788
-
Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm
-
Pan L, Xu J, Yu R et al. Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience. 2005; 133: 209-20
-
(2005)
Neuroscience
, vol.133
, pp. 209-220
-
-
Pan, L.1
Xu, J.2
Yu, R.3
-
29
-
-
0029113905
-
Antisense mapping the MOR-1 opioid receptor: Evidence for alternative splicing and a novel morphine-6 betaglucuronide receptor
-
Rossi GC, Pan YX, Brown GP, Pasternak GW. Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6 betaglucuronide receptor. FEBS Letters. 1995; 369: 192-6
-
(1995)
FEBS Letters
, vol.369
, pp. 192-196
-
-
Rossi, G.C.1
Pan, Y.X.2
Brown, G.P.3
Pasternak, G.W.4
-
32
-
-
27744431653
-
The endogenous opioid system and clinical pain management
-
Holden JE, Jeong Y, Forrest JM. The endogenous opioid system and clinical pain management. AACN Clinical Issues. 2005; 16: 291-301
-
(2005)
AACN Clinical Issues
, vol.16
, pp. 291-301
-
-
Holden, J.E.1
Jeong, Y.2
Forrest, J.M.3
-
34
-
-
3242747490
-
Cross-talk of opioid peptide receptor and beta-adrenergic receptor signalling in the heart
-
Pepe S, van den Brink OW, Lakatta EG, Xiao RP. Cross-talk of opioid peptide receptor and beta-adrenergic receptor signalling in the heart. Cardiovascular Research. 2004; 63: 414-22
-
(2004)
Cardiovascular Research
, vol.63
, pp. 414-422
-
-
Pepe, S.1
Van Den Brink, O.W.2
Lakatta, E.G.3
Xiao, R.P.4
-
35
-
-
0025581874
-
Endogenous opioids, the enteric nervous system and gut motility
-
Kromer W. Endogenous opioids, the enteric nervous system and gut motility. Digestive Diseases. 1990; 8: 361-73
-
(1990)
Digestive Diseases
, vol.8
, pp. 361-373
-
-
Kromer, W.1
-
36
-
-
29144445369
-
Multiple opioid receptors on immune cells modulate intracellular signaling. Brain
-
Sharp BM. Multiple opioid receptors on immune cells modulate intracellular signaling. Brain, Behavior, and Immunity. 2006; 20: 9-14
-
(2006)
Behavior, and Immunity
, vol.20
, pp. 9-14
-
-
Sharp, B.M.1
-
38
-
-
0016139515
-
Sites of morphine induced analgesia in the primate brain: Relation to pain pathways
-
Pert A, Yaksh T. Sites of morphine induced analgesia in the primate brain: relation to pain pathways. Brain Research. 1974; 80: 135-40
-
(1974)
Brain Research
, vol.80
, pp. 135-140
-
-
Pert, A.1
Yaksh, T.2
-
40
-
-
13844276195
-
Differentiation of opioid receptor preference by [Dmt1]endomorphin-2mediated antinociception in the mouse
-
Jinsmaa Y, Fujita Y, Shiotani K et al. Differentiation of opioid receptor preference by [Dmt1]endomorphin-2mediated antinociception in the mouse. European Journal of Pharmacology. 2005; 509: 37-42
-
(2005)
European Journal of Pharmacology
, vol.509
, pp. 37-42
-
-
Jinsmaa, Y.1
Fujita, Y.2
Shiotani, K.3
-
41
-
-
33746305665
-
Potent in vivo antinociception and opioid receptor preference of the novel analogue [Dmt(1)]endomorphin-1. Pharmacology
-
Jinsmaa Y, Marczak E, Fujita Y et al. Potent in vivo antinociception and opioid receptor preference of the novel analogue [Dmt(1)]endomorphin-1. Pharmacology, Biochemistry, and Behavior. 2006; 84: 252-8
-
(2006)
Biochemistry, and Behavior
, vol.84
, pp. 252-258
-
-
Jinsmaa, Y.1
Marczak, E.2
Fujita, Y.3
-
42
-
-
0034450970
-
Endomorphin-1 and endomorphin-2: Pharmacology of the selective endogenous mu-opioid receptor agonists
-
Horvath G. Endomorphin-1 and endomorphin-2: pharmacology of the selective endogenous mu-opioid receptor agonists. Pharmacology and Therapeutics. 2000; 88: 437-63
-
(2000)
Pharmacology and Therapeutics
, vol.88
, pp. 437-463
-
-
Horvath, G.1
-
43
-
-
0035993110
-
Isolation and distribution of endomorphins in the central nervous system
-
Zadina JE. Isolation and distribution of endomorphins in the central nervous system. Japanese Journal of Pharmacology. 2002; 89: 203-08
-
(2002)
Japanese Journal of Pharmacology
, vol.89
, pp. 203-208
-
-
Zadina, J.E.1
-
44
-
-
4644343161
-
Multiple opiate receptors: Deja vu all over again
-
Pasternak GW. Multiple opiate receptors: deja vu all over again. Neuropharmacology. 2004; 47 (Suppl. 1): 312-23
-
(2004)
Neuropharmacology
, vol.47
, pp. 312-323
-
-
Pasternak, G.W.1
-
45
-
-
0038014065
-
Utilizing functional genomics to identify new pain treatments: The example of nociceptin
-
Meunier JC. Utilizing functional genomics to identify new pain treatments: the example of nociceptin. American Journal of Pharmacogenomics. 2003; 3: 117-30
-
(2003)
American Journal of Pharmacogenomics
, vol.3
, pp. 117-130
-
-
Meunier, J.C.1
-
46
-
-
0026512239
-
Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic
-
Raffa RB, Friderichs E, Reimann W et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. Journal of Pharmacology and Experimental Therapeutics. 1992; 260: 275-85
-
(1992)
Journal of Pharmacology and Experimental Therapeutics
, vol.260
, pp. 275-285
-
-
Raffa, R.B.1
Friderichs, E.2
Reimann, W.3
-
47
-
-
33646455888
-
Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects
-
Yuan CS, Israel RJ. Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects. Expert Opinion on Investigational Drugs. 2006; 15: 541-52
-
(2006)
Expert Opinion on Investigational Drugs
, vol.15
, pp. 541-552
-
-
Yuan, C.S.1
Israel, R.J.2
-
48
-
-
0035138992
-
ADL 82698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia
-
Liu SS, Hodgson PS, Carpenter RL, Fricke Jr. JR. ADL 82698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clinical Pharmacology and Therapeutics. 2001; 69: 66-71
-
(2001)
Clinical Pharmacology and Therapeutics
, vol.69
, pp. 66-71
-
-
Liu, S.S.1
Hodgson, P.S.2
Carpenter, R.L.3
Fricke, J.R.4
-
49
-
-
0034693398
-
Improved bioavailability to the brain of glycosylated Met-enkephalin analogs
-
Egleton RD, Mitchell SA, Huber JD et al. Improved bioavailability to the brain of glycosylated Met-enkephalin analogs. Brain Research. 2000; 881: 37-46
-
(2000)
Brain Research
, vol.881
, pp. 37-46
-
-
Egleton, R.D.1
Mitchell, S.A.2
Huber, J.D.3
-
51
-
-
0034729726
-
Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability
-
Bilsky EJ, Egleton RD, Mitchell SA et al. Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability. Journal of Medicinal Chemistry. 2000; 43: 2586-90
-
(2000)
Journal of Medicinal Chemistry
, vol.43
, pp. 2586-2590
-
-
Bilsky, E.J.1
Egleton, R.D.2
Mitchell, S.A.3
-
52
-
-
0019493405
-
Increased food and water intake produced in rats by opiate receptor agonists
-
Sanger DJ, McCarthy PS. Increased food and water intake produced in rats by opiate receptor agonists. Psychopharmacology. 1981; 74: 217-20
-
(1981)
Psychopharmacology
, vol.74
, pp. 217-220
-
-
Sanger, D.J.1
McCarthy, P.S.2
-
53
-
-
0031885078
-
Pathophysiology and treatment of opioidrelated myoclonus in cancer patients
-
Mercadante S. Pathophysiology and treatment of opioidrelated myoclonus in cancer patients. Pain. 1998; 74: 5-9
-
(1998)
Pain
, vol.74
, pp. 5-9
-
-
Mercadante, S.1
-
55
-
-
0024218061
-
Endogenous and exogenous opioids in the control of gastrointestinal motility and secretion
-
Kromer W. Endogenous and exogenous opioids in the control of gastrointestinal motility and secretion. Pharmacological Reviews. 1988; 40: 121-62
-
(1988)
Pharmacological Reviews
, vol.40
, pp. 121-162
-
-
Kromer, W.1
-
57
-
-
3242741057
-
Chronic fentanyl or buprenorphine infusion in the mouse: Similar analgesic profile but different effects on immune responses
-
Martucci C, Panerai AE, Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain. 2004; 110: 385-92
-
(2004)
Pain
, vol.110
, pp. 385-392
-
-
Martucci, C.1
Panerai, A.E.2
Sacerdote, P.3
-
58
-
-
33745053647
-
Opioids and the immune system
-
Sacerdote P. Opioids and the immune system. Palliative Medicine. 2006; 20 (Suppl. 1): s9-15
-
(2006)
Palliative Medicine
, vol.20
, pp. s9-s15
-
-
Sacerdote, P.1
-
59
-
-
0034076414
-
The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients
-
Sacerdote P, Bianchi M, Gaspani L et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesthesia and Analgesia. 2000; 90: 1411-14
-
(2000)
Anesthesia and Analgesia
, vol.90
, pp. 1411-1414
-
-
Sacerdote, P.1
Bianchi, M.2
Gaspani, L.3
-
63
-
-
0003632704
-
-
Glenview, IL: American Academy of Pain Medicine, American Pain Society, American Society of Addiction Medicine
-
American Academy of Pain Medicine, American Pain Society, American Society of Addiction Medicine. Definitions related to the use of opioids for the treatment of pain. Glenview, IL: American Academy of Pain Medicine, American Pain Society, American Society of Addiction Medicine, 2001
-
(2001)
Definitions Related to the Use of Opioids for the Treatment of Pain
-
-
-
64
-
-
84900450171
-
Clinical pharmacology-including tolerance
-
Sykes N, Fallon MT, Patt RB, London: Arnold Publishers
-
Schug SA, Cardwell HMD. Clinical pharmacology-including tolerance. In: Sykes N, Fallon MT, Patt RB (eds). Clinical pain management: cancer pain. London: Arnold Publishers, 2003: 33-62
-
(2003)
Clinical Pain Management: Cancer Pain
, pp. 33-62
-
-
Schug, S.A.1
Cardwell, H.M.D.2
-
65
-
-
0024325328
-
Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model
-
Ling GS, Paul D, Simantov R, Pasternak GW. Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. Life Sciences. 1989; 45: 1627-36
-
(1989)
Life Sciences
, vol.45
, pp. 1627-1636
-
-
Ling, G.S.1
Paul, D.2
Simantov, R.3
Pasternak, G.W.4
-
66
-
-
0023510867
-
Cellular mechanisms of opioid tolerance: Studies in single brain neurons
-
Christie MJ, Williams JT, North RA. Cellular mechanisms of opioid tolerance: studies in single brain neurons. Molecular Pharmacology. 1987; 32: 633-8
-
(1987)
Molecular Pharmacology
, vol.32
, pp. 633-638
-
-
Christie, M.J.1
Williams, J.T.2
North, R.A.3
-
67
-
-
30644458052
-
Opioid tolerance in periaqueductal gray neurons isolated from mice chronically treated with morphine
-
Bagley EE, Chieng BC, Christie MJ, Connor M. Opioid tolerance in periaqueductal gray neurons isolated from mice chronically treated with morphine. British Journal of Pharmacology. 2005; 146: 68-76
-
(2005)
British Journal of Pharmacology
, vol.146
, pp. 68-76
-
-
Bagley, E.E.1
Chieng, B.C.2
Christie, M.J.3
Connor, M.4
-
69
-
-
0026518601
-
Pain, opioid use, and survival in hospitalized patients with advanced cancer
-
Brescia FJ, Portenoy RK, Ryan M et al. Pain, opioid use, and survival in hospitalized patients with advanced cancer. Journal of Clinical Oncology. 1992; 10: 149-55
-
(1992)
Journal of Clinical Oncology
, vol.10
, pp. 149-155
-
-
Brescia, F.J.1
Portenoy, R.K.2
Ryan, M.3
-
70
-
-
12344271040
-
Opioids: Cellular mechanisms of tolerance and physical dependence
-
Bailey CP, Connor M. Opioids: cellular mechanisms of tolerance and physical dependence. Current Opinion in Pharmacology. 2005; 5: 60-8
-
(2005)
Current Opinion in Pharmacology
, vol.5
, pp. 60-68
-
-
Bailey, C.P.1
Connor, M.2
-
72
-
-
34247622406
-
Addiction to opioids in chronic pain patients: A literature review
-
Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: A literature review. European Journal of Pain. 2007; 11: 490-518
-
(2007)
European Journal of Pain
, vol.11
, pp. 490-518
-
-
Hojsted, J.1
Sjogren, P.2
-
73
-
-
0029622428
-
The pharmacogenetics of codeine hypoalgesia
-
Sindrup SH, Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics. 1995; 5: 335-46
-
(1995)
Pharmacogenetics
, vol.5
, pp. 335-346
-
-
Sindrup, S.H.1
Brosen, K.2
-
76
-
-
0033901486
-
Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor
-
Gillen C, Haurand M, Kobelt DJ, Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. NaunynSchmiedeberg’s Archives of Pharmacology. 2000; 362: 116-21
-
(2000)
NaunynSchmiedeberg’s Archives of Pharmacology
, vol.362
, pp. 116-121
-
-
Gillen, C.1
Haurand, M.2
Kobelt, D.J.3
Wnendt, S.4
-
77
-
-
13244260911
-
The role of tramadol in cancer pain treatment a review
-
Leppert W, Luczak J. The role of tramadol in cancer pain treatment a review. Supportive Care in Cancer. 2005; 13: 5-17
-
(2005)
Supportive Care in Cancer
, vol.13
, pp. 5-17
-
-
Leppert, W.1
Luczak, J.2
-
78
-
-
33746171436
-
Extended-release tramadol in the treatment of osteoarthritis: A multicenter, randomized, double-blind, placebo-controlled clinical trial
-
Gana TJ, Pascual ML, Fleming RR et al. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Current Medical Research and Opinion. 2006; 22: 1391-401
-
(2006)
Current Medical Research and Opinion
, vol.22
, pp. 1391-1401
-
-
Gana, T.J.1
Pascual, M.L.2
Fleming, R.R.3
-
80
-
-
33646530497
-
Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: Lessons from tramadol
-
Epstein DH, Preston KL, Jasinski DR. Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biological Psychology. 2006; 73: 90-9
-
(2006)
Biological Psychology
, vol.73
, pp. 90-99
-
-
Epstein, D.H.1
Preston, K.L.2
Jasinski, D.R.3
-
81
-
-
0032877110
-
Tramadol relieves pain and allodynia in polyneuropathy: A randomised, double-blind, controlled trial
-
Sindrup SH, Andersen G, Madsen C et al. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain. 1999; 83: 85-90
-
(1999)
Pain
, vol.83
, pp. 85-90
-
-
Sindrup, S.H.1
Ersen, G.2
Madsen, C.3
-
83
-
-
0042347905
-
In search of a role for the morphine metabolite morphine-3-glucuronide
-
Vaughan CW, Connor M. In search of a role for the morphine metabolite morphine-3-glucuronide. Anesthesia and Analgesia. 2003; 97: 311-12
-
(2003)
Anesthesia and Analgesia
, vol.97
, pp. 311-312
-
-
Vaughan, C.W.1
Connor, M.2
-
84
-
-
34250688393
-
The adverse effects of morphine: A prospective survey of common symptoms during repeated dosing for chronic cancer pain
-
Glare P, Walsh D, Sheehan D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. American Journal of Hospice and Palliative Care. 2006; 23: 229-35
-
(2006)
American Journal of Hospice and Palliative Care
, vol.23
, pp. 229-235
-
-
Glare, P.1
Walsh, D.2
Sheehan, D.3
-
85
-
-
0037758126
-
Morphine and alternative opioids in cancer pain: The EAPC recommendations
-
Hanks GW, Conno F, Cherny N et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. British Journal of Cancer. 2001; 84: 587-93
-
(2001)
British Journal of Cancer
, vol.84
, pp. 587-593
-
-
Hanks, G.W.1
Conno, F.2
Cherny, N.3
-
86
-
-
12344291823
-
Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain
-
Hagen NA, Thirlwell M, Eisenhoffer J et al. Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain. Journal of Pain and Symptom Management. 2005; 29: 80-90
-
(2005)
Journal of Pain and Symptom Management
, vol.29
, pp. 80-90
-
-
Hagen, N.A.1
Thirlwell, M.2
Eisenhoffer, J.3
-
87
-
-
0025168461
-
The effect of prescribed daily dose frequency on patient medication compliance
-
Eisen SA, Miller DK, Woodward RS et al. The effect of prescribed daily dose frequency on patient medication compliance. Archives of Internal Medicine. 1990; 150: 1881-4
-
(1990)
Archives of Internal Medicine
, vol.150
, pp. 1881-1884
-
-
Eisen, S.A.1
Miller, D.K.2
Woodward, R.S.3
-
88
-
-
0343580459
-
Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain
-
Broomhead A, Kerr R, Tester W et al. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. Journal of Pain and Symptom Management. 1997; 14: 63-73
-
(1997)
Journal of Pain and Symptom Management
, vol.14
, pp. 63-73
-
-
Broomhead, A.1
Kerr, R.2
Tester, W.3
-
89
-
-
84892501827
-
Principles of oral analgesic therapy in cancer pain
-
Sykes N, Fallon MT, Patt RB, London: Arnold Publishers
-
Schug SA, Ritchie JE. Principles of oral analgesic therapy in cancer pain. In: Sykes N, Fallon MT, Patt RB (eds). Clinical pain management: cancer pain. London: Arnold Publishers, 2003: 123-41
-
(2003)
Clinical Pain Management: Cancer Pain
, pp. 123-141
-
-
Schug, S.A.1
Ritchie, J.E.2
-
90
-
-
28244480795
-
Analgesic drugs
-
Rang HP, Dale MM, Ritter JM, Moore PK, 5th edn. New York: Churchill Livingstone
-
Rang HP, Dale MM, Ritter JM, Moore PK. Analgesic drugs. In: Rang HP, Dale MM, Ritter JM, Moore PK (eds). Pharmacology, 5th edn. New York: Churchill Livingstone, 2003: 562-93
-
(2003)
Pharmacology
, pp. 562-593
-
-
Rang, H.P.1
Dale, M.M.2
Ritter, J.M.3
Moore, P.K.4
-
91
-
-
0031019623
-
Pharmacological characterization of buprenorphine, a mixed agonistantagonist with kappa 3 analgesia
-
Pick CG, Peter Y, Schreiber S, Weizman R. Pharmacological characterization of buprenorphine, a mixed agonistantagonist with kappa 3 analgesia. Brain Research. 1997; 744: 41-6
-
(1997)
Brain Research
, vol.744
, pp. 41-46
-
-
Pick, C.G.1
Peter, Y.2
Schreiber, S.3
Weizman, R.4
-
92
-
-
27144543526
-
Buprenorphine in cancer pain
-
Davis MP. Buprenorphine in cancer pain. Supportive Care in Cancer. 2005; 13: 878-87
-
(2005)
Supportive Care in Cancer
, vol.13
, pp. 878-887
-
-
Davis, M.P.1
-
94
-
-
33745960058
-
Long-term management of chronic pain with transdermal buprenorphine: A multicenter, open-label, follow-up study in patients from three short-term clinical trials
-
Likar R, Kayser H, Sittl R. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clinical Therapeutics. 2006; 28: 943-52
-
(2006)
Clinical Therapeutics
, vol.28
, pp. 943-952
-
-
Likar, R.1
Kayser, H.2
Sittl, R.3
-
95
-
-
33745036516
-
Transdermal buprenorphine in cancer pain and palliative care
-
Sittl R. Transdermal buprenorphine in cancer pain and palliative care. Palliative Medicine. 2006; 20 (Suppl. 1): s25-30
-
(2006)
Palliative Medicine
, vol.20
, pp. s25-s30
-
-
Sittl, R.1
-
96
-
-
11144344197
-
Pharmacology of high-dose buprenorphin
-
Kintz P, Marquet P, Totowa, NJ: Humana Press
-
Marquet P. Pharmacology of high-dose buprenorphin. In: Kintz P, Marquet P (eds). Buprenorphine therapy of opiate addiction. Totowa, NJ: Humana Press, 2002: 1-11
-
(2002)
Buprenorphine Therapy of Opiate Addiction
, pp. 1-11
-
-
Marquet, P.1
-
97
-
-
18944380310
-
Transdermal buprenorphine in the treatment of chronic pain
-
Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Expert Review of Neurotherapeutics. 2005; 5: 315-23
-
(2005)
Expert Review of Neurotherapeutics
, vol.5
, pp. 315-323
-
-
Sittl, R.1
-
98
-
-
0031018574
-
Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control
-
Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs. 1997; 53: 109-38
-
(1997)
Drugs
, vol.53
, pp. 109-138
-
-
Jeal, W.1
Benfield, P.2
-
99
-
-
33750322229
-
A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer
-
Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clinical Journal of Pain. 2006; 22: 805-11
-
(2006)
Clinical Journal of Pain
, vol.22
, pp. 805-811
-
-
Portenoy, R.K.1
Taylor, D.2
Messina, J.3
Tremmel, L.4
-
100
-
-
33847154665
-
Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate
-
Darwish M, Kirby M, Robertson Jr. P et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. Journal of Clinical Pharmacology. 2007; 47: 343-50
-
(2007)
Journal of Clinical Pharmacology
, vol.47
, pp. 343-350
-
-
Darwish, M.1
Kirby, M.2
Robertson, P.3
-
101
-
-
0028905662
-
Ketobemidone, methadone and pethidine are non-competitive N-methylD-aspartate (NMDA) antagonists in the rat cortex and spinal cord
-
Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methylD-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neuroscience Letters. 1995; 187: 165-8
-
(1995)
Neuroscience Letters
, vol.187
, pp. 165-168
-
-
Ebert, B.1
Ersen, S.2
Krogsgaard-Larsen, P.3
-
102
-
-
0036439851
-
Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence
-
Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clinical Pharmacokinetics. 2002; 41: 1153-93
-
(2002)
Clinical Pharmacokinetics
, vol.41
, pp. 1153-1193
-
-
Eap, C.B.1
Buclin, T.2
Baumann, P.3
-
103
-
-
0030928512
-
An update on the clinical use of methadone for cancer pain
-
Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain. 1997; 70: 109-15
-
(1997)
Pain
, vol.70
, pp. 109-115
-
-
Ripamonti, C.1
Zecca, E.2
Bruera, E.3
-
105
-
-
4544275588
-
Methadone versus morphine as a first-line strong opioid for cancer pain: A randomized, double-blind study
-
Bruera E, Palmer JL, Bosnjak S et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. Journal of Clinical Oncology. 2004; 22: 185-92
-
(2004)
Journal of Clinical Oncology
, vol.22
, pp. 185-192
-
-
Bruera, E.1
Palmer, J.L.2
Bosnjak, S.3
-
106
-
-
0035367176
-
Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: A prospective study
-
Mercadante S, Casuccio A, Fulfaro F et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. Journal of Clinical Oncology. 2001; 19: 2898-904
-
(2001)
Journal of Clinical Oncology
, vol.19
, pp. 2898-2904
-
-
Mercadante, S.1
Casuccio, A.2
Fulfaro, F.3
-
107
-
-
10044224657
-
Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain
-
Benitez-Rosario MA, Feria M, Salinas-Martin A et al. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. Cancer. 2004; 101: 2866-73
-
(2004)
Cancer
, vol.101
, pp. 2866-2873
-
-
Benitez-Rosario, M.A.1
Feria, M.2
Salinas-Martin, A.3
-
110
-
-
0037468688
-
Opioids and chronic neuropathic pain
-
Foley KM. Opioids and chronic neuropathic pain. New England Journal of Medicine. 2003; 348: 1279-81
-
(2003)
New England Journal of Medicine
, vol.348
, pp. 1279-1281
-
-
Foley, K.M.1
-
111
-
-
0033508630
-
Role of methadone in the management of pain in cancer patients
-
Bruera E, Neumann CM. Role of methadone in the management of pain in cancer patients. Oncology. 1999; 13: 1275-82
-
(1999)
Oncology
, vol.13
, pp. 1275-1282
-
-
Bruera, E.1
Neumann, C.M.2
-
113
-
-
33646151412
-
Oxycodone for cancer-related pain: Meta-analysis of randomized controlled trials
-
Reid CM, Martin RM, Sterne JA et al. Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. Archives of Internal Medicine. 2006; 166: 837-43
-
(2006)
Archives of Internal Medicine
, vol.166
, pp. 837-843
-
-
Reid, C.M.1
Martin, R.M.2
Sterne, J.A.3
-
114
-
-
0030819187
-
Controlled-release oxycodone and morphine in cancer related pain
-
Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain. 1997; 73: 37-45
-
(1997)
Pain
, vol.73
, pp. 37-45
-
-
Heiskanen, T.1
Kalso, E.2
-
115
-
-
0023795011
-
Hallucinations during morphine but not during oxycodone treatment
-
Kalso E, Vainio A. Hallucinations during morphine but not during oxycodone treatment. Lancet. 1988; 2: 912
-
(1988)
Lancet
, vol.2
, pp. 912
-
-
Kalso, E.1
Vainio, A.2
-
116
-
-
16844373756
-
Single-and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets
-
Adams MP, Ahdieh H. Single-and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs in R&D. 2005; 6: 91-9
-
(2005)
Drugs in R&D
, vol.6
, pp. 91-99
-
-
Adams, M.P.1
Ahdieh, H.2
-
118
-
-
0017580705
-
Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer
-
Beaver WT, Wallenstein SL, Houde RW, Rogers A. Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. Journal of Clinical Pharmacology. 1977; 17: 186-98
-
(1977)
Journal of Clinical Pharmacology
, vol.17
, pp. 186-198
-
-
Beaver, W.T.1
Wallenstein, S.L.2
Houde, R.W.3
Rogers, A.4
-
119
-
-
13244272132
-
Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: A pilot study
-
Sloan P, Slatkin N, Ahdieh H. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Supportive Care in Cancer. 2005; 13: 57-65
-
(2005)
Supportive Care in Cancer
, vol.13
, pp. 57-65
-
-
Sloan, P.1
Slatkin, N.2
Ahdieh, H.3
-
122
-
-
0034569462
-
D-morphine, but not L-morphine, has low micromolar affinity for the noncompetitive N-methyl-D-aspartate site in rat forebrain. Possible clinical implications for the management of neuropathic pain
-
Stringer M, Makin MK, Miles J, Morley JS. D-morphine, but not L-morphine, has low micromolar affinity for the noncompetitive N-methyl-D-aspartate site in rat forebrain. Possible clinical implications for the management of neuropathic pain. Neuroscience Letters. 2000; 295: 21-4
-
(2000)
Neuroscience Letters
, vol.295
, pp. 21-24
-
-
Stringer, M.1
Makin, M.K.2
Miles, J.3
Morley, J.S.4
-
123
-
-
0036323891
-
Clinical pharmacology of opioids for pain
-
Inturrisi CE. Clinical pharmacology of opioids for pain. Clinical Journal of Pain. 2002; 18: S3-13
-
(2002)
Clinical Journal of Pain
, vol.18
, pp. S3-S13
-
-
Inturrisi, C.E.1
-
124
-
-
33847139761
-
Levorphanol: The forgotten opioid
-
Prommer E. Levorphanol: the forgotten opioid. Supportive Care in Cancer. 2007; 15: 259-64
-
(2007)
Supportive Care in Cancer
, vol.15
, pp. 259-264
-
-
Prommer, E.1
-
125
-
-
37849014818
-
Opioid agonists and antagonists
-
Stoelting RK, Hillier SC, 4th edn. Philadelphia, PA: Lippincott Williams and Wilkins
-
Stoelting RK, Hillier SC. Opioid agonists and antagonists. In: Stoelting RK, Hillier SC (eds). Pharmacology and physiology in anesthetic practice, 4th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2006: 87-126
-
(2006)
Pharmacology and Physiology in Anesthetic Practice
, pp. 87-126
-
-
Stoelting, R.K.1
Hillier, S.C.2
-
126
-
-
17844387368
-
Plasma concentrations of meperidine and normeperidine following continuous intrathecal meperidine in patients with neuropathic cancer pain
-
Vranken JH, van der Vegt MH, van Kan HJ, Kruis MR. Plasma concentrations of meperidine and normeperidine following continuous intrathecal meperidine in patients with neuropathic cancer pain. Acta Anaesthesiologica Scandinavica. 2005; 49: 665-70
-
(2005)
Acta Anaesthesiologica Scandinavica
, vol.49
, pp. 665-670
-
-
Vranken, J.H.1
Van Der Vegt, M.H.2
Van Kan, H.J.3
Kruis, M.R.4
-
128
-
-
0026012840
-
Opioid agonist-antagonist drugs in acute and chronic pain states
-
Hoskin PJ, Hanks GW. Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs. 1991; 41: 326-44
-
(1991)
Drugs
, vol.41
, pp. 326-344
-
-
Hoskin, P.J.1
Hanks, G.W.2
-
130
-
-
0032076332
-
Nalmefene: A long-acting opioid antagonist. Clinical applications in emergency medicine
-
Wang DS, Sternbach G, Varon J. Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine. Journal of Emergency Medicine. 1998; 16: 471-5
-
(1998)
Journal of Emergency Medicine
, vol.16
, pp. 471-475
-
-
Wang, D.S.1
Sternbach, G.2
Varon, J.3
-
131
-
-
2942586206
-
Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects
-
discussion 9-22
-
Yuan CS. Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects. Journal of Supportive Oncology. 2004; 2: 111-17; discussion 9-22
-
(2004)
Journal of Supportive Oncology
, vol.2
, pp. 111-117
-
-
Yuan, C.S.1
-
132
-
-
20144366569
-
Alvimopan: An oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction a 21-day treatment-randomized clinical trial
-
Paulson DM, Kennedy DT, Donovick RA et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction a 21-day treatment-randomized clinical trial. Journal of Pain. 2005; 6: 184-92.
-
(2005)
Journal of Pain
, vol.6
, pp. 184-192
-
-
Paulson, D.M.1
Kennedy, D.T.2
Donovick, R.A.3
|